HRP20140097T1 - Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu - Google Patents
Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu Download PDFInfo
- Publication number
- HRP20140097T1 HRP20140097T1 HRP20140097AT HRP20140097T HRP20140097T1 HR P20140097 T1 HRP20140097 T1 HR P20140097T1 HR P20140097A T HRP20140097A T HR P20140097AT HR P20140097 T HRP20140097 T HR P20140097T HR P20140097 T1 HRP20140097 T1 HR P20140097T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- surfactant
- pharmaceutically acceptable
- less
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 23
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 10
- 239000004094 surface-active agent Substances 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- 229920002675 Polyoxyl Polymers 0.000 claims 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical group OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- -1 fatty acid ester Chemical class 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 239000001087 glyceryl triacetate Substances 0.000 claims 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 2
- 229960002622 triacetin Drugs 0.000 claims 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Tekući farmaceutski sastav, naznačen time, da obuhvaća:
(a) spoj (1) ili njegovu farmaceutski prihvatljivu sol:
[image]
u količini od 4,6% po masi ili manjoj;
(b) najmanje jedan tenzid od 10% do 30% po masi; i
(c) najmanje jedno farmaceutski prihvatljivo otapalo od 60% do 90% po masi;
gdje je omjer mase tenzida prema masi spoja (1) ili njegove farmaceutski prihvatljive soli, veći ili jednak 2,7;
dok je sastav uglavnom oslobođen od lipida,
te pri čemu sastav tvori bistru disperziju koja ima glavnu veličinu čestica manju od 1 ^m nakon razrjeđivanja ili otapanja u simuliranoj želučanoj tekućini.
2. Farmaceutski sastav prema zahtjevu 1, naznačen time, da tenzid ima hidrofilnu/lipofilnu ravnotežu veću od 10.
3. Farmaceutski sastav prema zahtjevu 1, naznačen time, da tenzid je vitamin E TPGS, polietoksilirano ricinusovo ulje, polioksil hidrogenirano ricinusovo ulje, ester polioksietilen sorbitanske masne kiseline, kaprilokaproil makrogolglicerid ili njihove mješavine.
4. Farmaceutski sastav prema zahtjevu 1, naznačen time, da farmaceutski prihvatljivo otapalo je propilenglikol, polipropilenglikol, polietilenglikol, glicerin, etanol, triacetin, dimetilizosorbid, glikofurol, propilenkarbonat, voda, dimetilacetamid ili njihove mješavine.
5. Farmaceutski sastav prema zahtjevu 1, naznačen time, da otapalo predstavlja mješavina od vode, polietilenglikola s prosječnom molekularnom masom većom od 300 ali manjom od 600, te propilenglikola.
6. Farmaceutski sastav prema zahtjevu 1, naznačen time, da taj farmaceutski sastav uopće ne sadrži lipide.
7. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je taj farmaceutski sastav uglavnom bez propilenglikola.
8. Farmaceutski sastav prema zahtjevu 1, naznačen time, da je taj farmaceutski sastav uglavnom bez amina.
9. Tekući farmaceutski sastav, naznačen time, da obuhvaća:
(a) spoj (1) ili njegovu farmaceutski prihvatljivu sol:
[image]
u količini od 6,3% po masi ili manjoj;
(b) najmanje jedan tenzid od 10% do 30% po masi; i
(c) najmanje jedno farmaceutski prihvatljivo otapalo od 60% do 90% po masi;
gdje je omjer mase tenzida prema masi spoja (1) ili njegove farmaceutski prihvatljive soli, veći ili jednak 4,3;
dok je sastav uglavnom oslobođen od lipida,
te pri čemu sastav tvori bistru disperziju koja ima glavnu veličinu čestica manju od 1 µm nakon razrjeđivanja ili otapanja u simuliranoj želučanoj tekućini.
10. Farmaceutski sastav prema zahtjevu 9, naznačen time, da tenzid ima hidrofilnu/lipofilnu ravnotežu veću od 10.
11. Farmaceutski sastav prema zahtjevu 9, naznačen time, da tenzid je vitamin E TPGS, polietoksilirano ricinusovo ulje, polioksil hidrogenirano ricinusovo ulje, ester polioksietilen sorbitanske masne kiseline, kaprilokaproil makrogolglicerid ili njihove mješavine.
12. Farmaceutski sastav prema zahtjevu 9, naznačen time, da farmaceutski prihvatljivo otapalo je propilenglikol, polipropilenglikol, polietilenglikol, glicerin, etanol, triacetin, dimetilizosorbid, glikofurol, propilenkarbonat, voda, dimetilacetamid ili njihove mješavine.
13. Farmaceutski sastav prema zahtjevu 9, naznačen time, da otapalo predstavlja mješavina od vode, polietilenglikola s prosječnom molekularnom masom većom od 300 ali manjom od 600, te od propilenglikola.
14. Farmaceutski sastav prema zahtjevu 9, naznačen time, da taj farmaceutski sastav uopće ne sadrži lipide.
15. Farmaceutski sastav prema zahtjevu 9, naznačen time, da je taj farmaceutski sastav uglavnom bez propilenglikola.
16. Farmaceutski sastav prema zahtjevu 9, naznačen time, da je taj farmaceutski sastav uglavnom bez amina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11678908P | 2008-11-21 | 2008-11-21 | |
| PCT/US2009/064908 WO2010059667A1 (en) | 2008-11-21 | 2009-11-18 | Pharmaceutical composition of a potent hcv inhibitor for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140097T1 true HRP20140097T1 (hr) | 2014-03-14 |
Family
ID=41650279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140097AT HRP20140097T1 (hr) | 2008-11-21 | 2014-02-04 | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20120101049A1 (hr) |
| EP (1) | EP2358355B1 (hr) |
| JP (1) | JP5553839B2 (hr) |
| KR (1) | KR20110087297A (hr) |
| CN (1) | CN102223875A (hr) |
| AR (1) | AR074391A1 (hr) |
| AU (1) | AU2009316755B2 (hr) |
| BR (1) | BRPI0921070A2 (hr) |
| CA (1) | CA2738732A1 (hr) |
| CL (1) | CL2011000878A1 (hr) |
| CO (1) | CO6361900A2 (hr) |
| CY (1) | CY1114892T1 (hr) |
| DK (1) | DK2358355T3 (hr) |
| EA (1) | EA022272B1 (hr) |
| EC (1) | ECSP11011065A (hr) |
| ES (1) | ES2445516T3 (hr) |
| HR (1) | HRP20140097T1 (hr) |
| IL (1) | IL211832A (hr) |
| MA (1) | MA32812B1 (hr) |
| ME (1) | ME01614B (hr) |
| MX (1) | MX2011005151A (hr) |
| MY (1) | MY155402A (hr) |
| NZ (1) | NZ592383A (hr) |
| PE (1) | PE20120032A1 (hr) |
| PL (1) | PL2358355T3 (hr) |
| PT (1) | PT2358355E (hr) |
| RS (1) | RS53121B (hr) |
| SG (1) | SG171771A1 (hr) |
| SI (1) | SI2358355T1 (hr) |
| TN (1) | TN2011000258A1 (hr) |
| TW (1) | TWI469801B (hr) |
| UA (1) | UA105777C2 (hr) |
| UY (1) | UY32252A (hr) |
| WO (1) | WO2010059667A1 (hr) |
| ZA (1) | ZA201102029B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| CA2767692C (en) * | 2009-07-07 | 2017-03-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| BR112013007423A2 (pt) | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | terapia combinada no que diz respeito ao tratamento da infecção por hcv |
| AU2011311880B2 (en) * | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
| JP2014506255A (ja) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| TWI532485B (zh) | 2011-10-21 | 2016-05-11 | 艾伯維有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）的方法 |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| BR112014006314A2 (pt) | 2011-10-21 | 2017-04-11 | Abbvie Inc | métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon |
| KR20140109433A (ko) * | 2012-01-12 | 2014-09-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 강력한 hcv 억제제의 안정화된 약제학적 제형 |
| JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| JP2015516421A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| MX2015013224A (es) | 2013-03-15 | 2015-12-11 | Gilead Sciences Inc | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| AU2002351169B2 (en) * | 2001-11-26 | 2007-09-20 | Intas Pharmaceuticals Limited | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| WO2004103996A1 (en) | 2003-05-21 | 2004-12-02 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CA2568008C (en) * | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
-
2009
- 2009-11-18 NZ NZ592383A patent/NZ592383A/xx not_active IP Right Cessation
- 2009-11-18 SG SG2011036498A patent/SG171771A1/en unknown
- 2009-11-18 CN CN2009801464655A patent/CN102223875A/zh active Pending
- 2009-11-18 SI SI200930810T patent/SI2358355T1/sl unknown
- 2009-11-18 MX MX2011005151A patent/MX2011005151A/es active IP Right Grant
- 2009-11-18 MY MYPI2011002269A patent/MY155402A/en unknown
- 2009-11-18 ES ES09760395.5T patent/ES2445516T3/es active Active
- 2009-11-18 UA UAA201107610A patent/UA105777C2/uk unknown
- 2009-11-18 JP JP2011537562A patent/JP5553839B2/ja not_active Expired - Fee Related
- 2009-11-18 CA CA2738732A patent/CA2738732A1/en not_active Abandoned
- 2009-11-18 DK DK09760395.5T patent/DK2358355T3/da active
- 2009-11-18 AU AU2009316755A patent/AU2009316755B2/en not_active Expired - Fee Related
- 2009-11-18 US US13/129,641 patent/US20120101049A1/en not_active Abandoned
- 2009-11-18 ME MEP-2013-140A patent/ME01614B/me unknown
- 2009-11-18 WO PCT/US2009/064908 patent/WO2010059667A1/en active Application Filing
- 2009-11-18 KR KR1020117011446A patent/KR20110087297A/ko not_active Application Discontinuation
- 2009-11-18 PT PT97603955T patent/PT2358355E/pt unknown
- 2009-11-18 PE PE2011001059A patent/PE20120032A1/es not_active Application Discontinuation
- 2009-11-18 RS RS20130583A patent/RS53121B/en unknown
- 2009-11-18 PL PL09760395T patent/PL2358355T3/pl unknown
- 2009-11-18 BR BRPI0921070A patent/BRPI0921070A2/pt not_active IP Right Cessation
- 2009-11-18 EA EA201100795A patent/EA022272B1/ru not_active IP Right Cessation
- 2009-11-18 EP EP09760395.5A patent/EP2358355B1/en active Active
- 2009-11-20 UY UY0001032252A patent/UY32252A/es not_active Application Discontinuation
- 2009-11-20 TW TW98139549A patent/TWI469801B/zh not_active IP Right Cessation
- 2009-11-20 AR ARP090104496A patent/AR074391A1/es unknown
-
2011
- 2011-03-17 ZA ZA2011/02029A patent/ZA201102029B/en unknown
- 2011-03-21 IL IL211832A patent/IL211832A/en not_active IP Right Cessation
- 2011-04-19 CL CL2011000878A patent/CL2011000878A1/es unknown
- 2011-05-20 TN TN2011000258A patent/TN2011000258A1/fr unknown
- 2011-05-20 EC EC2011011065A patent/ECSP11011065A/es unknown
- 2011-05-20 MA MA33867A patent/MA32812B1/fr unknown
- 2011-05-24 CO CO11063891A patent/CO6361900A2/es not_active Application Discontinuation
-
2014
- 2014-01-24 CY CY20141100063T patent/CY1114892T1/el unknown
- 2014-02-04 HR HRP20140097AT patent/HRP20140097T1/hr unknown
- 2014-10-17 US US14/517,242 patent/US20150038532A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140097T1 (hr) | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu | |
| ES2531646T3 (es) | Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno | |
| US9504656B2 (en) | Pharmaceutical compositions for poorly soluble active ingredients | |
| US20040052824A1 (en) | Micellar colloidal pharmaceutical composition containing a lipophilic active principle | |
| US20090155353A1 (en) | Microemulsions for pharmaceutical compositions | |
| RU2013100984A (ru) | Офтальмологические композиции для введения активных жирорастворимых ингредиентов | |
| PL191780B1 (pl) | Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji | |
| RS50842B (sr) | Meke kapsule koje sadrže palonosetron hlorovodonik koji ima poboljšanu stabilnost i bioraspoloživost | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| CA2554052A1 (en) | Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile | |
| HRP20160446T1 (hr) | Farmaceutski pripravci koji sadrže derivat kamptotecina | |
| WO2013191187A1 (ja) | 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物 | |
| JP2009503013A5 (hr) | ||
| JP2017503866A (ja) | デュタステリドを含む自己乳化型薬物送達システムのための組成物 | |
| WO2011073408A3 (en) | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | |
| HRP20171485T1 (hr) | Farmaceutski pripravci koji sadrže alisporivir | |
| CA2695605C (en) | Pyrazolone derivative emulsion formulations | |
| JP5750278B2 (ja) | カンデサルタンシレキセチルのカプセル充填用組成物 | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| ES2276110T3 (es) | Formulacion farmaceutica que incluye un inhibidor de renina no peptidico y un tensioactivo. | |
| KR20130109570A (ko) | 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물 | |
| JP6082503B1 (ja) | ソフトカプセル剤 | |
| US20200345646A1 (en) | Liquid filled formulations of pde5 inhibitors | |
| JP2008522972A5 (hr) | ||
| US11547677B2 (en) | Transmucosal delivery system for idebenone |